Related Experiment Video
Updated: Jan 29, 2026
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Disease Clearance Reduces the Risk of Adverse Outcomes and Provides Additional Benefit Beyond Individual Clinical,
Laura Ramos1,2,3, Raquel de la Barreda2, David Nicolás-Pérez2
1IBD Unit, Department of Gastroenterology, Hospital Universitario de Canarias. C/Ofra n/n, 38320 La Laguna, Spain.
Abstract:
Background and Aims: Recent advances in Ulcerative Colitis (UC) treatment have the potential to improve clinical outcomes if inflammation is controlled. The emerging concept of "disease clearance" (DC) aims to achieve combined clinical, endoscopic, and histological remission. However, whether DC is associated with better outcomes remains unclear. This study aimed to evaluate the impact of DC on UC patients. Methods: Consecutive UC patients who underwent colonoscopy and had clinical follow-up of at least 18 months were included between September 2012 and December 2017. Clinical condition (Patient-Reported Outcome, PRO), Mayo endoscopic score (MES), and histopathology (Geboes score, GS) were assessed at baseline and every 6 months. Disease clearance (DC) was defined as simultaneous clinical remission (PRO2 = 0), endoscopic remission (MES = 0), and histological remission (GS ≤ 2). Results: A total of 101 UC patients with a median time since diagnosis of 103 ± 102 months were included. At baseline colonoscopy, 52 patients (51.5%) achieved DC. These subjects had a lower rate of negative outcomes than those without DC (21.2% vs. 59.2%, p < 0.001). Kaplan-Meier curves confirmed a lower risk of clinical relapse in DC patients (log-rank, p = 0.001). Among patients with endoscopic remission, only those with DC had a lower risk of negative outcomes (21.2% vs. 75%, p < 0.01). Achieving DC reduced the risk of flare-ups even in patients with clinical remission or histological remission. Conclusions: Achieving DC in UC patients reduces the risk of negative outcomes during follow-up, supporting its inclusion as a key composite treatment goal in UC management.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...